Precision Therapies and HCP Education Propel Q3 2025 OC, EC, and Pan-Tumor Promotions

During Q3 2025, the ovarian, endometrial, and pan-tumor market centered on HCP-targeted digital content, featuring biomarker-informed therapies, the latest clinical research, and medical education opportunities.

AstraZeneca emphasized Imfinzi’s survival data in dMMR endometrial cancer and medical education on personalized treatment for gynecologic cancers.

Jemperli materials introduced a new visual campaign, fostered HCP engagement with brand resources, and provided unbranded DTC content promoting awareness and support initiatives.

FDA approval for Keytruda Qlex positioned the subcutaneous formulation as a convenient treatment option for solid tumors, offering patient-centered benefits to reduce treatment burden.

New Zejula data was featured at a conference, which explored maintenance treatment outcomes, real-world insights, and quality of life findings. Unbranded DTC content promoted awareness and support initiatives.